Aimovig And Tegsedi In Raft Of Products To Get EMA Thumbs up

Approval applications for nine products received a positive opinion this week from the European Medicines Agency’s drug evaluation committee, the CHMP, and one product was turned down.

3d render of Europe map Earth globe
Nine new products have been recommended for approval across the EU

Novartis and Amgen’s first-of-its-kind migraine drug, Aimovig (erenumab), and Akcea Therapeutics’ new treatment for patients with hereditary transthyretin amyloidosis, Tegsedi (inotersen), are among nine products that the European Medicines Agency this week recommended for approval across the EU.

The other drugs that received a positive opinion from the agency’s Committee for Medicinal Products for Human Use (CHMP) during...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet